Subscribe
shutterstock_1492661771_ricochet64-1
ricochet64 / Shutterstock.com
25 January 2022Big PharmaMuireann Bolger

Mylan gets green light to challenge Neurim melatonin patent

Mylan has been allowed to challenge Neurim's melatonin patent at trial following a ruling by the High Court of England and Wales that the generic drug maker did not contravene the legal principle of estoppel.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Mylan’s NHK-Fintiv challenge denied by SCOTUS
20 January 2022   The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.
Big Pharma
English High Court denies Mylan a stay in Neurim litigation
2 November 2021   Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.
Big Pharma
English High Court rejects second injunction bid over melatonin medicine
30 June 2022   Justice Mellor was unconvinced by arguments that Teva could have cleared the way.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Mylan’s NHK-Fintiv challenge denied by SCOTUS
20 January 2022   The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.
Big Pharma
English High Court denies Mylan a stay in Neurim litigation
2 November 2021   Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.
Big Pharma
English High Court rejects second injunction bid over melatonin medicine
30 June 2022   Justice Mellor was unconvinced by arguments that Teva could have cleared the way.

More on this story

Americas
Mylan’s NHK-Fintiv challenge denied by SCOTUS
20 January 2022   The US Supreme Court has rejected a bid from generic drugmaker Mylan to overturn the NHK-Fintiv rule.
Big Pharma
English High Court denies Mylan a stay in Neurim litigation
2 November 2021   Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.
Big Pharma
English High Court rejects second injunction bid over melatonin medicine
30 June 2022   Justice Mellor was unconvinced by arguments that Teva could have cleared the way.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers